Abstracts Archive - Page 36 of 2607 - ACR Meeting Abstracts

Abstract Number: 0264 • ACR Convergence 2025
Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease
Mohamed Tharwat Hegazy, Rania Yacoub, Sarah Sheta, Rana Hussein Amin and Noha Khalil, Faculty of Medicine, Cairo University, Cairo, Egypt
Background/Purpose: Vogt-Koyanagi-Harada disease (VKH) is a systemic disease that affects the central nervous system, ocular, and integumentary system. It causes bilateral granulomatous uveitis, dysacusia ranging…
Abstract Number: 0246 • ACR Convergence 2025
Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS
Marco Di Paola¹, Fiorella Anna Lombardi¹, Edmund J MacLaughlin², Maurizio Muratore³, Kathleen Methric⁴, Gianmarco Del Vecchio⁵, Giusy Peluso⁶, Chiara Stomaci⁷, Roberto Franchini¹, Francesco Conversano¹, Paola Pisani¹ and Sergio Casciaro¹, ¹Institute of Clinical Physiology, National Research Council, Lecce, Puglia, Italy, ²Rheumatology Associates of Delmarva and BoneVue Diagnostics, Easton, MD, ³ASL- LE, "Vito Fazzi" Hospital, Lecce, Puglia, Italy, ⁴BoneVue Diagnostics, Catonsville, MD, ⁵Department of Research and Development, Echolight S.p.a., Lecce, Puglia, Italy, ⁶Department of Innovative Engineering, University of Salento, Lecce, Puglia, Italy, ⁷Department of Biological and Envinronmental Sciences and Technologies, University of Salento, Lecce, Puglia, Italy
Background/Purpose: Intestinal Bowel Diseases (IBD), including Crohn’s (ChD), and Ulcerative Colitis (UCD), along with Celiac (ClD), diseases are chronic inflammatory conditions that primarily affect the…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 0132 • ACR Convergence 2025
Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
Fanshu Li, Ranran Yao, Fanlei Hu, Liling Xu and Chun Li, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China (People's Republic)
Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…
Abstract Number: 0157 • ACR Convergence 2025
Influence of Outpatient Clinic Visits on Receipt of the COVID-19 Vaccine among People with Autoimmune Rheumatic Diseases
Lesley Jackson¹, Nicole Wright², Rahima Begum³, Fazlur Rahman¹, Rena Patel¹, Kenneth Saag⁴, Jeffrey Curtis⁵ and Maria I. ("Maio") Danila⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Tulane University School of Medicine, New Orleans, LA, ³University of Alabama at Birmingham, Birmingham, ⁴The University of Alabama at Birmingham, Birmingham, AL, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL
Background/Purpose: Rheumatologists and primary care providers (PCPs) are some of the most trusted clinicians for people living with autoimmune rheumatic diseases (AIRD), and they may…
Abstract Number: 0141 • ACR Convergence 2025
Cytokine profiles in antiphospholipid syndrome
Xiangjun Liu¹, Yuzhou Gan², Chun Li³, Jianping Guo⁴, lei zhu⁵ and yuan jia³, ¹Peking University, Beijing, Beijing, China, ²University of Michigan, Ann Arbor, MI, ³Peking University People's Hospital, Beijing, China (People's Republic), ⁴Peking University People's Hospital, Beijing, Beijing, China, ⁵Affiliated Nantong Rehabilitation Hospital of Nantong University, Nantong, China (People's Republic)
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disease with unknown etiology. Inflammatory-mediated tissue damage plays an important role in APS. This study aimed to investigate…
Abstract Number: 2281 • ACR Convergence 2025
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study
Louis Bessette¹, Andrew Chow², Raman Rai³, Hugues Allard-Chamard⁴, Pauline Boulos⁵, Guylaine Roy⁶ and Dalinda Liazoghli⁶, ¹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ²Credit Valley Rheumatology, Mississauga, McMaster University, Hamilton, University of Toronto, Toronto, ON, Canada, ³Drs. Rai & Sekhon Medicine Professional Corporation, Brampton, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶AbbVie Corporation, Saint-Laurent, QC, Canada
Background/Purpose: Upadacitinib (UPA) is an oral, selective Janus kinase (JAK)-inhibitor proven effective and well-tolerated in patients with rheumatoid arthritis (RA) in 6 randomized clinical trials.…
Abstract Number: 0226 • ACR Convergence 2025
Integration of the 5Ms of Geriatrics in a Novel Geri-Rheumatology Clinic
Justin Levinson¹ and Christie Bartels², ¹University of Wisconsin- Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Geriatric integrative care models, such as the Perioperative Optimization of Senior Health (POSH) initiative, have shown improved outcomes (PMID: 29299599), yet there remains limited…
Abstract Number: 0297 • ACR Convergence 2025
Longitudinal Serum Proteomic Profiles – A Step Closer to Personalized Monitoring in Dermatomyositis
Natasha Le Blanc¹, Marie Hudson¹, Ana Cristina Gonzalez Sanchez², Lina Marcela Diaz Gallo² and Valerie Leclair³, ¹McGill University, Montréal, QC, Canada, ²Karolinska Institutet, Stockholm, Sweden, ³McGill University, Montréal, Canada
Background/Purpose: Dermatomyositis (DM) is a multisystemic immune mediated disease presenting with heterogeneous clinical features. Disease monitoring in DM relies in part on biomarkers of muscle…
Abstract Number: 0230 • ACR Convergence 2025
An Epic journey – Therapeutic Drug Monitoring at an Academic Center
Puja Khanna¹ and Michael Rice², ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Gastroenterology, University of Michigan, Ann Arbor, MI
Background/Purpose: Non-oncologic use of immunomodulatory agents is increasing. These drugs have a narrow, patient-specific therapeutic index, making therapeutic drug monitoring essential for safe prescribing. However,…
Abstract Number: 0265 • ACR Convergence 2025
Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis
Mohammed Mohammed¹, Bindee Kuriya², Lihi Eder¹, Elsie Nguyen³, Shadi Ahktari⁴, Paula Harvey⁵, Wei Wu⁶ and Sohan Shahab⁷, ¹University of Toronto, Toronto, ON, Canada, ²University of Toronto - Toronto, Toronto, ON, Canada, ³University of Toronto, Toronto, ⁴University of Toronto Department of Medicine and Women's College Hospital, Toronto, Canada, ⁵University of Toronto Department of Medicine and Women's College Hospital, Toronto, ON, Canada, ⁶University of Toronto, Toronto, Canada, ⁷Women’s College Research Institute, Women’s College Hospital, Toronto, Canada
Background/Purpose: Patients with inflammatory arthritis (IA) have increased cardiovascular risk. Coronary artery calcium (CAC) scoring by computed tomography (CT) detects early coronary disease and structural…
Abstract Number: 0273 • ACR Convergence 2025
Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis
Synat Keam¹, Yuanteng Li², Yanshuo Chu¹, Jean Tayar³, Huifang Lu⁴, Michael Wu⁵, Sandeep Agarwal⁶, Nitin Jain⁷, Pavlos Msaouel¹, Adi Diab², Cara Haymaker¹, Linghua Wang¹, Roza Nurieva⁸ and Sang Kim⁹, ¹The University of Texas MD Anderson Cancer Center, houston, ²MD Anderson Cancer Center, Houston, TX, ³The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴UT MD Anderson Cancer Center, Houston, TX, ⁵Baylor College of Medicine, Houston, ⁶Baylor College of Medicine, Houston, TX, ⁷The Universty of Texas MD Anderson Cancer Center, Houston, ⁸University of Texas MD Anderson, Houston, TX, ⁹Yale University, Branford, CT
Background/Purpose: Immune checkpoint inhibitor (ICI) therapy is associated with life- and/or organ-threatening immune-related adverse events, including inflammatory arthritis (ICI-IA). However, the mechanisms behind ICI-IA, especially…
Abstract Number: 0054 • ACR Convergence 2025
Microbial Cues Promote Arthritis and Alter T Cell Selection in SKG Mice
Astha Patel¹, Steven yu¹, Yuka Nakao¹, Mohana Mukherjee¹, Diego Orellana², Jose Scher³, Peter Turnbaugh¹, Renuka Nayak⁴ and Judith Ashouri¹, ¹University of California, San Francisco, San Francisco, CA, ²University of California San Francisco, San Francisco, CA, ³New York University School of Medicine, New York, NY, ⁴University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Dysbiosis of the gut microbiota has been linked to rheumatoid arthritis (RA), but it remains unclear whether these microbial alterations are causal or secondary…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 0325 • ACR Convergence 2025
Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
C. Kent Kwoh¹, Amanda Nelson², Rongrong Tang³, Edward J. Bedrick³, Yong Ge¹, Yvonne Golightly⁴, Zong-Ming Li³, Jean Liew⁵, Xiaoxiao Sun¹, Jeffrey Duryea⁶ and Tuhina Neogi⁵, ¹The University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³The University of Arizona Arthritis Center, University of Arizona, Tucson, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Boston University School of Medicine, Boston, MA, ⁶Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].